Targeted Delivery of Immunomodulators to Lymph Nodes
暂无分享,去创建一个
L. Tang | U. V. von Andrian | J. Azzi | R. Abdi | Jianjun Cheng | M. McGrath | S. Tullius | O. Maarouf | S. Loughhead | Qian Yin | Kaimin Cai | Mincheol Kwon | Eirini Kefaloyianni | S. Ohori | T. Ichimura | M. Uehara | J. Petr | Qidi Sun
[1] Mauro Ferrari,et al. Principles of nanoparticle design for overcoming biological barriers to drug delivery , 2015, Nature Biotechnology.
[2] T. Kupper,et al. The emerging role of resident memory T cells in protective immunity and inflammatory disease , 2015, Nature Medicine.
[3] J. Azzi,et al. Serine Protease Inhibitor‐6 Differentially Affects the Survival of Effector and Memory Alloreactive CD8‐T Cells , 2015, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.
[4] Xiaoyan Zhang,et al. Recent advances in lymphatic targeted drug delivery system for tumor metastasis , 2014, Cancer biology & medicine.
[5] P. Choyke,et al. Cancer Drug Delivery: Considerations in the Rational Design of Nanosized Bioconjugates , 2014, Bioconjugate chemistry.
[6] Samir Mitragotri,et al. Overcoming the challenges in administering biopharmaceuticals: formulation and delivery strategies , 2014, Nature Reviews Drug Discovery.
[7] Steven T. Wang,et al. Central memory CD8+ T lymphocytes mediate lung allograft acceptance. , 2014, The Journal of clinical investigation.
[8] S. Miller,et al. A Biodegradable Nanoparticle Platform for the Induction of Antigen-Specific Immune Tolerance for Treatment of Autoimmune Disease , 2014, ACS nano.
[9] S. Stacker,et al. Lymphangiogenesis and lymphatic vessel remodelling in cancer , 2014, Nature Reviews Cancer.
[10] Gregory L. Szeto,et al. Structure-based programming of lymph-node targeting in molecular vaccines , 2014, Nature.
[11] Hea‐Young Cho,et al. Nano-sized drug delivery systems for lymphatic delivery. , 2014, Journal of nanoscience and nanotechnology.
[12] J. Azzi,et al. Calcineurin Inhibitors: 40 Years Later, Can’t Live Without … , 2013, The Journal of Immunology.
[13] C. Ricordi,et al. Long-Term Heart Transplant Survival by Targeting the Ionotropic Purinergic Receptor P2X7 , 2013, Circulation.
[14] Francisco J. Quintana,et al. Nanoparticle-mediated codelivery of myelin antigen and a tolerogenic small molecule suppresses experimental autoimmune encephalomyelitis , 2012, Proceedings of the National Academy of Sciences.
[15] J. Hubbell,et al. Nano-sized drug-loaded micelles deliver payload to lymph node immune cells and prolong allograft survival. , 2011, Journal of Controlled Release.
[16] M. Uesaka,et al. Accumulation of sub-100 nm polymeric micelles in poorly permeable tumours depends on size. , 2011, Nature nanotechnology.
[17] D. Irvine,et al. In situ engineering of the lymph node microenvironment via intranodal injection of adjuvant-releasing polymer particles , 2011, Proceedings of the National Academy of Sciences.
[18] N. Zhang,et al. Targeting Lymphangiogenesis After Islet Transplantation Prolongs Islet Allograft Survival , 2011, Transplantation.
[19] Li Tang,et al. Polylactide‐cyclosporin A nanoparticles for targeted immunosuppression , 2010, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[20] Baohui Xu,et al. Alpha4beta7 integrin/MAdCAM-1 adhesion pathway is crucial for B cell migration into pancreatic lymph nodes in nonobese diabetic mice. , 2010, Journal of autoimmunity.
[21] T. Fan,et al. The Formulation of Aptamer-coated Paclitaxel–polylactide Nanoconjugates and Their Targeting to Cancer Cells , 2022 .
[22] J. Bluestone,et al. Prevention of Diabetes by FTY720-Mediated Stabilization of Peri-Islet Tertiary Lymphoid Organs , 2010, Diabetes.
[23] W. Seo,et al. PSGL‐1 function in immunity and steady state homeostasis , 2009, Immunological reviews.
[24] T. Xia,et al. Understanding biophysicochemical interactions at the nano-bio interface. , 2009, Nature materials.
[25] C. Gleissner,et al. Glycosylation in immune cell trafficking , 2009, Immunological reviews.
[26] R. Oberbauer,et al. Calcineurin inhibitor minimization, withdrawal and avoidance protocols after kidney transplantation , 2009, Transplant international : official journal of the European Society for Organ Transplantation.
[27] Jianjun Cheng,et al. Paclitaxel-initiated, controlled polymerization of lactide for the formulation of polymeric nanoparticulate delivery vehicles. , 2008, Angewandte Chemie.
[28] G. Klintmalm,et al. Calcineurin inhibitor‐sparing regimens in solid organ transplantation: focus on improving renal function and nephrotoxicity , 2007, Clinical transplantation.
[29] Sai T Reddy,et al. Exploiting lymphatic transport and complement activation in nanoparticle vaccines , 2007, Nature Biotechnology.
[30] Volker Wagner,et al. The emerging nanomedicine landscape , 2006, Nature Biotechnology.
[31] J. Chapman,et al. Nephrotoxicity of ciclosporin A: short-term gain, long-term pain? , 2006, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.
[32] N. Tolkoff-Rubin,et al. 2005 Immunosuppressive Strategies in Kidney Transplantation: Which Role for the Calcineurin Inhibitors? , 2005, Transplantation.
[33] S. Lira,et al. Lymph Node Occupancy Is Required for the Peripheral Development of Alloantigen-Specific Foxp3+ Regulatory T Cells1 , 2005, The Journal of Immunology.
[34] Fadi G Lakkis,et al. Lymphoid Neogenesis in Murine Cardiac Allografts Undergoing Chronic Rejection , 2005, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.
[35] Philip F Halloran,et al. Immunosuppressive drugs for kidney transplantation. , 2004, The New England journal of medicine.
[36] U. V. von Andrian,et al. Lymphocyte–HEV Interactions in Lymph Nodes of a Sulfotransferase-deficient Mouse , 2003, The Journal of experimental medicine.
[37] Ulrich H. von Andrian,et al. Homing and cellular traffic in lymph nodes , 2003, Nature Reviews Immunology.
[38] E. Butcher,et al. Chemokines in the systemic organization of immunity , 2003, Immunological reviews.
[39] M. Sayegh,et al. Memory T cells: a hurdle to immunologic tolerance. , 2003, Journal of the American Society of Nephrology : JASN.
[40] Baohui Xu,et al. Lymphocyte Homing to Bronchus-associated Lymphoid Tissue (BALT) Is Mediated by L-selectin/PNAd, α4β1 Integrin/VCAM-1, and LFA-1 Adhesion Pathways , 2003, The Journal of experimental medicine.
[41] S. Akira,et al. Critical role of the Toll-like receptor signal adaptor protein MyD88 in acute allograft rejection. , 2003, The Journal of clinical investigation.
[42] M. Sayegh,et al. The Role of the CD134-CD134 Ligand Costimulatory Pathway in Alloimmune Responses In Vivo 1 , 2003, The Journal of Immunology.
[43] M. Sayegh,et al. Responses In Vivo Costimulatory Pathway in Alloimmune The Role of the CD 134-CD 134 Ligand Yagita and , 2003 .
[44] G. Storm,et al. Liposomes to target the lymphatics by subcutaneous administration. , 2001, Advanced drug delivery reviews.
[45] S. Michie,et al. Lymphocyte migration to inflamed lacrimal glands is mediated by vascular cell adhesion molecule-1/alpha(4)beta(1) integrin, peripheral node addressin/l-selectin, and lymphocyte function-associated antigen-1 adhesion pathways. , 2001, The American journal of pathology.
[46] David R. Moore,et al. Polymerization of lactide with zinc and magnesium beta-diiminate complexes: stereocontrol and mechanism. , 2001, Journal of the American Chemical Society.
[47] W. Somers,et al. Insights into the Molecular Basis of Leukocyte Tethering and Rolling Revealed by Structures of P- and E-Selectin Bound to SLeX and PSGL-1 , 2000, Cell.
[48] C. Mackay,et al. T-cell function and migration. Two sides of the same coin. , 2000, The New England journal of medicine.
[49] Fadi G Lakkis,et al. Immunologic ‘ignorance’ of vascularized organ transplants in the absence of secondary lymphoid tissue , 2000, Nature Medicine.
[50] K. Wood,et al. T-cell activation, proliferation, and memory after cardiac transplantation in vivo. , 1999, Annals of surgery.
[51] M. D. de Broe,et al. A meta-analysis and morphological review of cyclosporine-induced nephrotoxicity in auto-immune diseases. , 1998, Kidney international.
[52] O. Simell,et al. Recirculation and homing of lymphocyte subsets: dual homing specificity of beta 7-integrin(high)-lymphocytes in nonobese diabetic mice. , 1996, Blood.
[53] L. Picker,et al. Lymphocyte Homing and Homeostasis , 1996, Science.
[54] E. A. O'neill,et al. T cell responses in calcineurin A alpha-deficient mice , 1996, The Journal of experimental medicine.
[55] L. Picker,et al. The human peripheral lymph node vascular addressin. An inducible endothelial antigen involved in lymphocyte homing. , 1993, The American journal of pathology.
[56] E. Berg,et al. Comparison of L-selectin and E-selectin ligand specificities: the L-selectin can bind the E-selectin ligands sialyl Le(x) and sialyl Le(a). , 1992, Biochemical and biophysical research communications.
[57] E. Berg,et al. The human peripheral lymph node vascular addressin is a ligand for LECAM-1, the peripheral lymph node homing receptor , 1991, The Journal of cell biology.
[58] E. Butcher,et al. Immunohistologic and functional characterization of a vascular addressin involved in lymphocyte homing into peripheral lymph nodes , 1988, The Journal of cell biology.
[59] G. Kolata. Drug transforms transplant medicine. , 1983, Science.
[60] A. Corry. 1973 meeting in kansas city. , 1973, Bulletin of the Medical Library Association.